A fact-check found the Guardian’s menopause hormone therapy article was largely accurate despite social media attacks branding it “drivel” and “badly researched.”
The review said the piece correctly presented MHT as the most effective treatment for hot flashes and night sweats, with evidence-backed bone benefits, while rejecting claims it prevents dementia, heart disease or premature death.
Its main criticism was one ambiguous line on cardiovascular health and the omission of breast-cancer risk from combined therapy, which the analyst said rises about 30% after 6 years.
The backlash, the analyst argued, reflects a wider “menopause gold rush” in which influencers, clinics and products profit from overstating MHT as a cure-all in a market worth $10-15 billion a year.
That commercialization has grown out of real failures in women’s care, but the piece says replacing past underprescribing with one-size-fits-all hormone marketing risks sidelining evidence again.